Following exposure to radiation and chemotherapeutic agents, the epidermal growth factor receptor (EGFR) can modulate the repair of DNA double-strand breaks (DSB) by forming protein complexes that include the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs). This is one of the key mechanism by which tumors become resistant to DNA-damaging therapies. Our previous studies have shown that insulin-like growth factor binding protein-3 (IGFBP-3) is a substrate for DNA-PKcs, and can transactivate EGFR. We therefore questioned whether IGFBP-3 might interact with the EGFR À DNA-PK complex that regulates the DNA damage response. The aim of this study was to delineate the role of IGFBP-3 in the response of breast cancer cells to DSBinducing chemotherapeutic agents. In the estrogen receptor-negative breast cancer cell lines MDA-MB-468 and Hs578T, which express IGFBP-3 highly, nuclear localization of EGFR and IGFBP-3 was enhanced by treatment with cytotoxic drugs etoposide or doxorubicin and reduced by the EGFR kinase inhibitor gefitinib. Enhanced association among IGFBP-3, EGFR and DNA-PKcs, following the exposure to DNA-damaging drugs was supported by both co-immunoprecipitation analysis and direct visualization by proximity ligation assay. The activation of DNA-PKcs at Ser2056, DNA repair as measured by a nonhomologous end-joining assay, and the increase in EGFR and DNA-PKcs interaction induced by DNA-damaging agents, were all decreased by IGFBP-3 silencing, suggesting that IGFBP-3 has an obligatory role in the DNA repair response to DNA-damaging therapy. In conclusion, IGFBP-3 co-translocation to the nucleus of breast cancer cells and its formation of a complex with DNA-PKcs and EGFR in response to DNA damage shows its potential involvement in the regulation of DNA repair. This suggests the possibility of a therapeutic approach for sensitizing breast cancer to chemo-or radiotherapy by targeting the DNA repair function of IGFBP-3.
INTRODUCTION
Breast cancer is the most common form of cancer in women, and the second leading cause of cancer-related death among females worldwide. 1, 2 Although the five-year survival rate for cancer confined to the breast has increased to about 80-90% in the last decade, approximately one-third of all breast cancer patients still die from the disease because metastatic breast cancer remains generally incurable. 3 DNA-damaging therapy, including radiotherapy or cytotoxic chemotherapy, is an important weapon against advanced breast cancer. However, cancer cells frequently develop resistance to either ionizing radiation or cytotoxic agents, and the precise mechanism by which they do so is still unclear. There is increasing evidence that the receptor tyrosine kinase, epidermal growth factor receptor (EGFR), has an important role in this process. EGFR has been shown to confer tumor resistance to radiotherapy through radiation-induced nuclear translocation of the receptor and its interaction with the DNAdependent protein kinase (DNA-PK) complex, a key component of the DNA repair pathway. 4 Targeting the DNA repair function of EGFR may serve as a therapeutic model for sensitizing tumors to radiotherapy in patients. 5 However, only limited benefit has been obtained from combining the treatment with EGFR inhibitors, and overall response rates are still low in most patients. 6, 7 Therefore, further studies are necessary to determine if other signaling pathways may oppose the DNA-damaging process.
We have previously reported functional interactions between both EGFR and DNA-PK, and insulin-like growth factor binding protein-3 (IGFBP-3). 8, 9 IGFBP-3 is one of a family of six high-affinity proteins that regulate the function of insulin-like growth factors by modulating their interaction with their tyrosine kinase receptor (IGF1R). IGFBP-3 is the most abundant IGFBP in the adult circulation, acting as the main carrier of insulin-like growth factor-I and -II. 10 Although it can exert tumor suppressive properties through both insulin-like growth factor-dependent and -independent mechanisms, 11 IGFBP-3 may also be growthstimulatory in a range of cell types in vitro. Consistent with this, high tissue levels of IGFBP-3 mRNA or protein are associated with markers of poor prognosis in a variety of cancers, [12] [13] [14] [15] including breast cancer. [16] [17] [18] One mechanism by which IGFBP-3 promotes breast tumor survival may involve its interaction with the molecular chaperone GRP78, leading to increased cell autophagy. 19 We have also previously reported that IGFBP-3 can transactivate EGFR through the activation of sphingosine kinase 1, has been reported by others to be important in the induction of apoptosis by IGFBP-3. 22 In the present study, we investigated the contribution of EGFR and IGFBP-3 nuclear translocation to the response to cytotoxic drugs in breast cancer cells, and found that IGFBP-3 has a facilitating role in this process.
RESULTS
DNA-PKcs phosphorylation induced by DNA-damaging agents is associated with EGFR activation and nuclear accumulation DNA-PKcs contains multiple Ser/Thr phosphorylation sites, and its DNA damage-inducible autophosphorylation site at Ser2056 is required for the repair of double-strand breaks (DSB) by nonhomologous end joining (NHEJ). 23 In MDA-MB-468 breast cancer cells, the DNA-damaging agent etoposide induced DNAPKcs phosphorylation at Ser2056, observed predominantly in nuclei as early as 30 min following the treatment and maintained for at least 6 h ( Figure 1a ). To determine whether the phosphorylation of EGFR and its nuclear accumulation is temporally associated with DNA-PKcs activation, western blotting was used to examine the phosphorylation of both proteins in breast cancer cell nuclear extracts, following etoposide treatment. Phosphorylated EGFR and DNA-PKcs both showed a time-dependent accumulation in the nucleus, following treatment with 20 mM etoposide ( Figure 1b) . The relative purity of the nuclear fractions was confirmed by undetectable levels of the cytosolic and mitochondrial marker proteins a-tubulin and Tim23, respectively, compared with the nuclear marker protein lamin B1. Quantitation of western blots showed that the phosphorylation of nuclear EGFR on Y1068 increased over time (Figure 1c ), while the total EGFR levels in the nucleus increased after 2 h treatment, but then declined (Figure 1d ). In contrast, total DNA-PKcs in the nucleus was unchanged over the 4-h period. A similar increase, and then decline, in nuclear EGFR was seen in Hs578T breast cancer cells treated with 20 mM etoposide or 1 mM doxorubicin, although the time-course was slower ( Supplementary Figures S1A and B) .
Nuclear localization of EGFR and IGFBP-3 is enhanced by etoposide and blocked by EGFR kinase inhibition As endogenous IGFBP-3 contributes to EGFR activation by EGF in MCF-10A mammary epithelial cells, 20 we examined whether it also influenced the EGFR response to DNA damage. Cells were serumstarved for 16 h before treatment with etoposide alone or in combination with the EGFR kinase inhibitor gefitinib (10 mM), and then harvested at different time points and the nuclear fractions isolated. Increases in nuclear EGFR (Figures 2a and b , also seen in Figures 1b and d) and IGFBP-3 (Figures 2a and c) were detectable at 2 h following etoposide treatment, declining at 4 h, whereas total DNA-PKcs levels did not change (Figure 2a) . The etoposideinduced increase of both EGFR and IGFBP-3 in nuclear fractions was entirely blocked by the addition of the EGFR kinase inhibitor gefitinib (Figures 2d-f) , suggesting that EGFR kinase activity is necessary for nuclear import of both EGFR and IGFBP-3 in response to DNA damage.
The interaction of IGFBP-3 with EGFR and DNA-PKcs is enhanced, following etoposide treatment, and reversed by EGFR kinase inhibition Immunoprecipitation using Fab fragments of IGFBP-3 antibodies showed co-precipitation of both EGFR and DNA-PKcs with IGFBP-3 Figure 1 . Etoposide induced DNA-PKcs phosphorylation is associated with EGFR activation and nuclear accumulation. (a) MDA-MB-468 breast cancer cells were treated with 20 mM etoposide for 0-6 h, then immunostained with anti-pSer2056-DNA-PKcs antibody, followed by secondary antibody labeled with Alexa Fluor 633. DNA was stained with DAPI. Analysis was performed by confocal microscopy. (b) Nuclei from cells treated as above were isolated at the times shown after treatment, and proteins were separated by SDS-PAGE followed by western blotting. Tubulin, lamin B1 and TIM23 were measured as markers for cytosol, nuclei and mitochondria, respectively. in the cytoplasmic and nuclear fractions of MDA-MB-468 cells, suggesting that these proteins interact in one or more complexes (Figure 3a) . IGFBP-3-EGFR complexes increased in the cytoplasm, and slightly in the nucleus, following etoposide treatment (Figure 3b ), whereas IGFBP-3-DNA-PKcs complexes showed an increase only in the nuclear fraction, significant at 4 h (Figure 3c ). The increases in IGFBP-3-EGFR and IGFBP-3-DNA-PKcs complexes in response to etoposide treatment were entirely blocked in the presence of gefitinib (Figures 3d-f ). Similar patterns were observed for complexes between IGFBP-3 and phosphoforms of EGFR and DNA-PKcs (Figure 3g ), providing evidence for the co-translocation of IGFBP-3 with phosphorylated EGFR to the nucleus, 1-2 h after exposure to etoposide, followed by an increase in association of IGFBP-3 with phospho-DNA-PKcs over 4 h of treatment. The peak of IGFBP-3 association with total and phospho-DNA-PKcs, 4 h after etoposide exposure, corresponds to a time when total nuclear IGFBP-3 is declining (Figures 2a and c) . As IGFBP-3 binding appears to be associated with DNA-PKcs phosphorylation on Ser2056-which peaks at 4 h or later (Figure 1a )-we assume that increased phospho-DNA-PKcs drives this complex despite declining nuclear IGFBP-3.
The interactions among IGFBP-3, EGFR and DNA-PKcs were further demonstrated by proximity ligation assay (PLA, Duolink), which allows visualization of the interaction between pairs of proteins in fixed cells. Each interaction is represented by a single far-red fluorescent dot. Figure 4a shows that IGFBP-3-EGFR complexes increased over the 4 h of etoposide treatment. As was shown using co-immunoprecipitation in Figure 3a , the complexes visualized by PLA were predominantly cytoplasmic, but both the total complex and the nuclear proportion increased within 1-2 h of treatment (Figure 4b ). IGFBP-3-EGFR complex formation, quantitated at 4 h, was blocked by gefitinib treatment (Figures 4c and d) , again confirming the need for active EGFR kinase. The EGFR-DNA-PKcs interaction (Figure 4e ) was significantly increased 4 h after etoposide treatment, with a marked increase in the proportion of the interactions visualized within the nucleus (Figure 4f ). The increase in this interaction was also blocked by gefitinib. In contrast to the other protein interactions, the IGFBP-3-DNA-PKcs interaction was predominantly nuclear even before etoposide treatment (Figures 4g and h) , with both the extent of interaction and the proportion within the nucleus further increased 4 h after the treatment. Again, these changes were blocked by gefitinib.
Together these co-immunoprecipitation and PLA results are consistent with a sequence of events in which IGFBP-3 forms a binary complex with EGFR in response to DNA damage; the complex translocates to the nucleus over 1-2 h, and at 4 h increased complexes between DNA-PKcs and both IGFBP-3 and EGFR are seen, possibly reflecting the formation of a ternary complex among these proteins. However, at 4 h, total nuclear IGFBP-3 is in decline, consistent with a reported half-life of o1 h for nuclear, as opposed to extranuclear, IGFBP-3. 24 These interactions can be blocked by pretreating the cells with EGFR kinase inhibitor, indicating the requirement for EGFR phosphorylation in both protein complex formation and nuclear translocation in MDA-MB-468 breast cancer cells. The nuclear localization of protein complexes in response to DNA-damaging treatment was verified by examining confocal z-stack sections at the center of the cell nucleus (not shown). Confirming the specificity of the EGFR-IGFBP-3 interaction, no complex was detectable between EGFR and either IGFBP-1 or insulin-like growth factor-II, tested as negative controls (Supplementary Figure S2) . IGFBP-3 is required for nuclear translocation of the protein complex and initiation of DNA repair To further confirm the involvement of IGFBP-3 in the nuclear translocation of the protein complex and DNA-PK activation, the distribution of EGFR-DNA-PKcs complexes in response to etoposide treatment was studied with or without the IGFBP-3 downregulation by siRNA in MDA-MB-468 cells. By PLA and confocal microscopy, most of the EGFR-DNA-PKcs complexes were extranuclear in untreated cells (Figure 5a ). There was a significant increase in the intensity of fluorescent signals in response to etoposide treatment, and a significantly greater proportion localized to the nucleus (Figure 5c ). Over this period, nuclear complexes increased by 3.9-fold in absolute terms. In contrast, when the cells were pretreated with IGFBP-3 siRNA, the increases in EGFR-DNA-PKcs complexes and their nuclear translocation were completely blocked (Figure 5d ), suggesting that IGFBP-3 is required for the formation of EGFR-DNA-PKcs complex and for its relative nuclear accumulation. Immunocytochemistry indicated B80% knockdown of IGFBP-3 levels 48 h post-transfection with IGFBP-3 siRNA compared with control siRNA (Figures 5e and f) . A second anti-IGFBP-3 siRNA targeted to a distinct sequence confirmed these results (Supplementary Figure S3) .
Western blotting analysis (Figure 6a ) of the effect of these two IGFBP-3 siRNAs indicated that autophosphorylation of DNA-PKcs at Ser2056 in response to etoposide was decreased when IGFBP-3 was silenced (quantitated in Figure 6b ). Immunofluorescence To examine whether the role of IGFBP-3 in DNA-PKcs autophosphorylation was reflected in an effect on DNA repair after etoposide-induced DSB damage, a cell-free assay for NHEJ repair was used. In this method, a plasmid, cut with two restriction enzymes to generate a DNA fragment with nonhomologous ends, is incubated with nuclear extracts from treated cells, yielding DNA bands of increased size when analyzed by agarose gel electrophoresis. 25 As shown in Figure 6e , treatment of the purified DNA fragment for 30 min with a nuclear extract from control MDA-MB-468 cells generated several larger DNA bands, which were increased in intensity when the nuclear extract was prepared from 4-h etoposide-treated cells. Downregulation of IGFBP-3 using two different siRNAs attenuated etoposide-stimulated DNA repair, supporting the interpretation that IGFBP-3 has a direct role in the DNA repair function of DNA-PKcs.
IGFBP-3 decreases cell survival after DNA damage Despite its facilitating role in DNA DSB repair, we 26 and others 27 have previously described an inhibitory effect of exogenous or overexpressed IGFBP-3 on cell survival after DNA-damaging treatments. We therefore examined the role of endogenous IGFBP-3 on survival in response to DSB-inducing drugs. As shown in Supplementary Figure S4 , downregulation of IGFBP-3 using two different siRNAs increased the survival response of Hs578T cells to 5 mM etoposide or 0.1 mM doxorubicin exposure, measured in clonogenic survival assays over 8-10 days. This experiment was not performed in MDA-MB-468 cells, as they formed colonies very poorly (data not shown). Thus IGFBP-3 appears to be involved in both repair of DNA damage and inhibition of cell survival; it may therefore have both a 'caretaker' and a 'gatekeeper' role 28 in breast cancer cells.
Colocalization of the protein complex with lipid rafts is reduced by DNA-damaging agents A variety of cell surface receptors, including EGFR, and other signaling molecules, are concentrated in specialized plasma membrane domains known as lipid rafts, 29 which localize and transport signaling proteins and other lipid raft-associated molecules. 30, 31 Lipid rafts are defined by their resistance to extraction with nonionic detergents and their low density in sucrose gradients. It has been reported that the actions of IGFBP-3 are mediated through its secretion then reuptake by clathrinindependent endocytosis via caveolin-enriched lipid rafts and clathrin-dependent endocytosis of IGFBP-3-transferrin complexes. 32 To determine whether lipid rafts are involved in EGFR and IGFBP-3 nuclear translocation in response to DNAdamaging treatment, confocal microscopy was used to identify colocalization of EGFR-IGFBP-3 complexes with glycosphingolipids that bind cholera toxin subunit B (CT-B), a marker for lipid rafts. 33 Figure 7a shows that the EGFR-IGFBP-3 complexes observed by PLA in cells exposed to etoposide were partly associated with lipid rafts, visualized as CT-B conjugated with FITC, and their colocalization was decreased over 2-4 h of treatment (Figure 7b) . In contrast, the interaction between EGFR and IGFBP-3 was enhanced following the etoposide treatment (Figure 7c ). We also assessed the presence of individual proteins within lipid rafts by western blotting of fractions isolated by gradient centrifugation, and re-localization in response to DNA-damaging agents. As shown in Supplementary Figure S5 , the plasma membrane lipid raft fraction from MDA-MB-468 cells was found to reside mainly in the lower-density fractions 4 or 5 of the sucrose density gradient, which contain caveolin-1 as a marker for this domain. 34 The components of the EGFR and DNA-PKcs complex were detected in this detergent-insoluble low-density fraction, and the presence of EGFR and DNA-PK in lipid rafts was reduced by the DNA-damaging agent doxorubicin (Supplementary Figure S5A) , interpreted as a re-localization of both proteins away from this compartment. Gefitinib treatment increased both EGFR and DNA-PKcs in caveolin-rich fractions, and blocked the doxorubicin-induced decrease in both proteins in lipid rafts (Supplementary Figure S5B) . These findings are consistent with the interpretation that EGFR and DNA-PKcs may localize in lipid rafts, and their movement out of these domains in response to DNA-damaging agents requires EGFR kinase activity. However, we were unable to detect IGFBP-3 in lipid raft components by western blot analysis, so it is not possible to determine whether a ternary complex involving IGFBP-3, EGFR and DNA-PKcs might exist, even transiently, in this fraction.
DISCUSSION
In higher eukaryotes, there are two distinct mechanisms to protect cells from DNA DSBs induced by DNA-damaging agents: homologous recombination and nonhomologous end joining (NHEJ). Studies with mice deficient in components of each of the two DNA repair systems suggest that NHEJ is the dominant pathway, whereas homologous recombination has a supportive role. 35 The DNA-PK complex, which comprises a heterodimer of 70-and 80-kDa proteins termed Ku70/80 and a 465-kDa serine/threonine protein kinase catalytic subunit DNA-PKcs, 36 has been shown to have an essential role in the process of NHEJ. 37 EGFR belongs to a large family of receptor tyrosine kinases that mediate many important physiological processes in both normal and cancer cells. EGFR is best known for its classical role as a plasma membrane-bound receptor which has a central role in the tumorigenesis and malignancy of many cancers. Emerging evidence suggests that nuclear EGFR, a result of either constitutive presence or treatment-induced nuclear translocation, may have an important role in the therapy-resistant phenotype. 38 Radiation induces translocation of EGFR to the nucleus 5 where it interacts with DNA-PKcs and functions as a transcription factor to regulate gene expression required for DNA repair, 39 thereby promoting repair of radiation-induced DSBs in DNA. Overexpression of DNAPKcs in cancers can result in increased resistance to DNA damage, 40 and cells lacking Ku (the DNA DSB-targeting components of DNA-PK) or DNA-PKcs are sensitive to DNAdamaging therapy. 41 Of relevance to the present study, the increase in DNA-PK activation associated with the translocation of EGFR to the nucleus could be inhibited by treatment with a monoclonal antibody against EGFR. 5 In this study, we confirmed that similar to ionizing radiation, cytotoxic drugs such as etoposide and doxorubicin, which cause DNA DSBs, could induce nuclear import of EGFR, and this translocation was associated with the initiation of DNA-PK activation. These results are consistent with several previous studies using cisplatin, another cytotoxic chemotherapy drug, which indicated that nuclear EGFR is essential for the development of resistance to cisplatin and for DNA repair. 42 The EGFR tyrosine kinase inhibitor gefitinib can inhibit EGFR nuclear translocation, indicating that gefitinib could modulate repair of DNA damage, following exposure to etoposide or cisplatin. 43 Notwithstanding the demonstrated role of EGFR in tumor resistance to DNA-damaging therapy, a study of women with breast cancer receiving gefitinib and docetaxel indicated that optimal effects of EGFR inhibition occurred mostly (70%) in women with estrogen receptor (ER)-positive tumors, whereas complete or partial responses occurred in only 21% of patients with ER-negative tumors. 44 This is despite EGFR being more highly expressed in ERnegative tumors than ER-positive. 45 Unlike breast cancer patients with ER-positive status, who usually have relatively better prognosis as ER has proven to be a successful target of cancer therapy, the treatment for patients with ER-negative breast cancer is still a challenge. 46 One major problem is the development of tumor resistance to radiation or cytotoxic chemotherapy.
In ER-negative breast cancers, several other proteins have been identified as being overexpressed compared with ER-positive tumors, including IGFBP-3. 47, 48 Despite well-documented growthinhibitory effects of IGFBP-3 in vitro and its ability to potentiate the apoptotic effect of some chemotherapeutic drugs, 11 positive associations between IGFBP-3 and breast tumor grade or risk have also been observed in clinical studies. [49] [50] [51] The evidence presented in this paper highlights the dual actions of endogenous IGFBP-3 in response to agents that induce DSB DNA damage: it promotes DNA-PKcs activation and stimulates DNA repair by NHEJ, which may assist in the maintenance of genomic integrity, while also increasing apoptosis and decreasing cell survival, which may serve to eliminate cells with damaged DNA. Together with the previous observation that IGFBP-3 can also regulate cell cycle activity by increasing p27 and decreasing cyclin D1 and pRb(Ser795) in breast cancer cells, 52 our findings are consistent with both a 'gatekeeper' function for IGFBP-3, 28,53 and a previously unrecognized 'caretaker' function, that is, a positive role for IGFBP-3 in facilitating the DNA DSB repair response. Other examples of proteins described as sharing gatekeeper (tumor suppressor or cell cycle checkpoint) and caretaker (DNA repair) functions include ARF 54 and BRCA1. 55, 56 Although the precise mechanisms of these dual effects of IGFBP-3 remain unclear, some evidence suggests the microenvironment of the tumor may have an important role. McIntosh et al. 57 found IGFBP-3 can inhibit EGF-induced growth of breast cancer cells cultured on plastic; but with the same cells on fibronectin, the action of IGFBP-3 switched to promoting EGFinduced proliferation, suggesting that matrix proteins around the tumor may modulate the biological functions of IGFBP-3 and its impact on EGFR signaling. We also recently reported that IGFBP-3 can stimulate autophagy in oxygen-and nutrient-starved breast cancer cells by forming a complex with GRP78. 19 Recent evidence suggests that the induction of autophagy may be involved in repair signaling after DNA damage. 58 Therefore, it is possible that in the microenvironment of solid tumors, IGFBP-3-stimulated autophagy might contribute to enhanced survival after exposure to DNA-damaging therapy. If this is so, IGFBP-3 expressing breast tumors might be particularly susceptible to combination therapies that target these pathways. These findings may explain in part our previous observation that breast cancer cells expressing IGFBP-3 grow more aggressively as xenograft tumors in nude mice than corresponding tumors that do not express IGFBP-3, 21 and the numerous clinical studies in which high expression of IGFBP-3 mRNA or protein in breast tumor tissue is associated with markers of poor prognosis. 16, 18 This may also help to explain some of the conflicting findings for IGFBP-3 actions from cell culture, animal studies and clinical data.
The question of how IGFBP-3 facilitates nuclear translocation of EGFR and the activation of DNA-PKcs remains unanswered, although several possibilities arise. We have reported that IGFBP-3 has a functional nuclear localization signal, 59 and that its nuclear translocation involves interaction with importin-b. 60 EGFR similarly has a defined nuclear localization signal domain, mutation of which impairs its association with, and activation of, DNA-PKcs. 61 Through direct interaction of the two proteins, IGFBP-3 may enhance EGFR internalization and nuclear translocation, as our previous studies in MCF-10A cells indicated that IGFBP-3 can potentiate the activation of EGFR, 9 which may lead to an increase in EGFR internalization. 62, 63 In this process, internalization of EGFR with caveolin-1 is regarded as an essential step. 62 The internalization of IGFBP-3 has also been found to be mediated by a caveolin-dependent pathway 64 and may be followed by nuclear import. 32, 65 In the present study, we confirmed that the DNAdamaging agents etoposide and doxorubicin could induce protein complex nuclear trafficking, resulting in lower amounts of EGFR and DNA-PKcs detected in lipid raft components. Significantly, inhibition of EGFR activation blocked this translocation, resulting in the accumulation of EGFR and DNAPKcs in lipid rafts. Localization of EGFR within lipid raft components correlates with resistance to EGFR kinase inhibitorinduced growth inhibition. 66 Second, the formation of protein complexes with IGFBP-3 may stabilize EGFR and DNA-PK complexes and promote their nuclear translocation, which is essential for DNA-PKcs activation and DNA repair in response to DNA-damage. In this study, we have provided clear evidence that downregulation of IGFBP-3 expression completely abolished the etoposide-induced increase in EGFR and DNA-PKcs complex formation and nuclear accumulation in MDA-MB-468 cells. As a third possibility, IGFBP-3 may stimulate the autophosphorylation of DNA-PKcs directly through protein complex formation. Our studies using both co-IP analysis and PLA indicated maximum interaction between IGFBP-3 and EGFR was observed within 2 h of treatment with etoposide, whereas the effects on IGFBP-3 and DNA-PKcs interaction become significant a little later and lasted longer (Figures 3 and 4) . This raises the possibility that the binding of IGFBP-3 with EGFR promotes its nuclear translocation to initiate DNA-PKcs activation, and nuclear IGFBP-3 interacts with DNA-PKcs to further maintain the phosphorylation of DNA-PKcs.
In summary, our findings indicate that the role of IGFBP-3 as a regulator of human breast cancer cell growth and survival is complex. On the one hand, co-translocation of IGFBP-3 with EGFR to the nucleus appears to be required for DNA-PKcs autophosphorylation and the DNA repair response, while on the other hand, it promotes the apoptotic response of tumor cells, following DNA-damaging therapy. A better understanding of these newly discovered intracellular functions of IGFBP-3 may lead to a novel approach toward treatment to overcome therapeutic resistance in women with breast cancer.
MATERIALS AND METHODS Materials
Tissue culture reagents and plasticware were from Trace Biosciences (North Ryde, New South Wales, Australia) and Nunc (Roskilde, Denmark). Antibodies were from the following sources: anti-EGFR (Cell Signaling, Beverly, MA, USA, #2232); anti-Y1068-phospho-EGFR (D7A5) (Cell Signaling, #3777); anti-DNA-PKcs (BD Pharmingen, San Jose, CA, USA, #556456); anti-S2056-phospho-DNA-PKcs (Abcam, Cambridge, UK, #4407); anti-calnexin (Abcam, ab10286); anti-lamin B1 (Calbiochem, Alexandria, NSW, Australia, #NA12); anti-a-tubulin (Sigma, Sydney, NSW, Australia, #T5168); anti-Tim23 (BD Transduction Labs, #611222); caveolin-1 (BD Transduction Labs, North Ryde, NSW, Australia, #610407); rabbit antihuman IGFBP-3 antiserum (R100) was produced in our laboratory. All secondary antibodies were obtained from GE Healthcare, Rydalmere, New South Wales, Australia. Doxorubicin and etoposide were from Sigma and the EGFR inhibitor gefitinib was purchased from LC Laboratories, Woburn, MA, USA.
Cell culture
The ER negative human breast cancer cell lines Hs578T and MDA-MB-468, both with high level of endogenous EGFR and IGFBP-3, were obtained from the American Type Culture Collection (Manassas, VA, USA), and tested negative for mycoplasma contamination monthly. Both were maintained in RPMI 1640 medium containing 5% fetal calf serum and 10 mg/ml bovine insulin at 37 1C and 5% CO 2 .
siRNA-mediated protein silencing
Silencing of IGFBP-3 was achieved in MDA-MB-468 cells using siRNA duplexes both custom-designed (#1) and validated (SI02780589, #2) by Qiagen (Doncaster, VIC, Australia). The sequence for the custom-designed antisense IGFBP-3 siRNAs was r(5 0 -UCUGAGACUCGUAGUCAAC-3 0 )dTdT. For gene knockdown, the cells were harvested by trypsinization and resuspended at 1 Â 10 6 cells in 100 ml Transfection Reagent solution V (Lonza, Cologne, Germany), then mixed with 100 nM targeting siRNA or AllStars negative control siRNA (Qiagen). Nucleoporation was carried out using an Amaxa electroporation unit (Lonza), according to the manufacturer's instructions. Immediately after electroporation, cells were transferred to complete medium, then plated for analysis as described below. Knockdown of IGFBP-3 expression was confirmed by western analysis and immunocytochemistry.
Cellular fractionation and western blotting analyses
Cellular fractionation was performed according to the manufacturer's protocol for the NE-PER Nuclear and Cytoplasmic Extraction Kit (Pierce, Rockford, IL, USA). Briefly, CER solution was added to cell pellets, incubated for 10 min and the supernatant cytoplasmic extracts were removed. Nuclear pellets were suspended in NER solution, incubated for 40 min and supernatants containing nuclear extracts collected. To obtain whole-cell lysates, cells were lysed in Laemmli sample buffer (62.5 mM Tris-HCl pH 6.8, containing 20 g/l SDS, 100 ml/l glycerol, 1 g/l bromphenol blue and 50 mM dithiothreitol) at 4 1C for 10 min, then sonicated. Samples were heated at 90 1C for 5 min immediately before loading onto 4-12% NuPAGE Bis-Tris precast gels (Invitrogen, Carlsbad, CA, USA). After transfer, the membranes were blocked for 1 h, and then incubated with primary antibodies overnight at 4 1C, followed by horseradish peroxidase-labeled secondary antibodies. PageRuler pre-stained protein ladder for electrophoresis were obtained from Thermo Scientific (Waltham, MA, USA) and washed filters were developed by enhanced chemiluminescence using Supersignal West Pico Chemiluminescent substrate (Pierce). Filters were imaged using a Luminescent Image Analyzer LAS-3000 (Fujifilm, Stamford, CT, USA), and quantified using Image Gauge software (Fujifilm, Science Lab). To confirm fraction purity and equal loading, proteins known to localize in different subcellular fractions were analyzed as internal controls: cytosol or wholecell lysate, a-tubulin or b-actin; mitochondria/membranes, Tim23; nucleus, lamin B1.
Immunoprecipitation
Cells at 80-90% confluency were lysed with ice-cold RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with a protease and phosphatase inhibitor cocktail (Roche, Castle Hill, NSW, Australia) at 4 1C for 30 min. To precipitate IGFBP-3, cell lysates were incubated overnight with 50 ml suspension of agarose beads (Affi-Gel 10, Bio-Rad, Hercules, CA, USA) that had been conjugated with anti-IGFBP-3 Fab fragments, digested and purified from rabbit anti-human IGFBP-3 IgG, according to the Fab Preparation Kit (Pierce, #44685). After conjugation, the beads were blocked with excess Tris-HCl pH 7.5 before use. To evaluate nonspecific precipitation, Affi-Gel 10 agarose beads blocked with excess Tris-HCl, but containing no antibody, were used. After centrifugation, the immunoprecipitated samples were resuspended in Laemmli sample buffer and boiled at 95-100 1C for 5 min before electrophoresis.
DNA repair assay
The cell-free DNA end-joining assay was performed as described by Andrin et al., 25 based on the method of Feldmann et al. 67 To prepare nuclear extracts, MDA-MB-468 cells were transfected with control or anti-IGFBP-3 siRNA as described above and, after 24 h, treated with 20 mM etoposide for 4 h. High-salt nuclear extracts were prepared essentially as described by Andrin et al. 68 Briefly, after isolation of nuclei by centrifugation through a buffer containing 300 mM sucrose, the washed nuclear pellet was extracted into high-salt buffer (20 mM Hepes, pH 7.5, 25% glycerol, 420 mM NaCl, 0.2 mM EDTA, 1.5 mM MgCl 2 ) for 30 min on ice, and insoluble material was removed by centrifugation. The soluble nuclear extract was used in the end-joining assay.
A DNA fragment with nonhomologous ends was generated by digesting the plasmid pEGFP-C1 (Clontech, Mountain View, CA, USA) with restriction enzymes NheI and EcoRI (New England Biolabs, Ipswich, MA, USA). The linearized plasmid was separated by 0.8% agarose gel electrophoresis, purified using a DNA gel extraction kit (Promega, Madison, WI, USA), and used as the substrate for end-joining assays. Nuclear extract (5 mg) was diluted with end-joining assay buffer as described 25 and allowed to stand for 5 min at room temperature. The repair assay, according to Andrin et al., 25 was run at 25 1C for 30-60 min, stopped and analyzed as described, and the DNA bands stained with SYBR Green I (Invitrogen) and visualized on a LAS-3000 Image Analyzer (Fujifilm).
Confocal microscopy
Cultured cells grown on glass coverslips were washed three times with PBS, fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.2% Triton X-100 for 5 min and blocked with 20 g/l BSA for 1 h. Cells were then incubated with primary antibodies overnight at 4 1C, washed, and further incubated with the appropriate secondary antibody, tagged with Alexa Fluor 633 dye (Invitrogen, Life Technologies, Mulgrave, VIC, Australia). For controls, cells were treated with isotype-matched IgG from the same species. Slides were mounted using ProLong Gold Antifade Reagent containing 4 0 -6-diamidino-2-phenylindole (DAPI) (Invitrogen). Confocal fluorescence images were captured with a Leica SP5 confocal laser scanning microscope (Leica Microsystems, Wetzlar, Germany). The images were captured in the middle sections of nuclei and statistical analyses were performed with the Leica confocal LAS AF Lite software (version 1.7.0 build 1240). The intracellular distribution of fluorescence intensity was quantified using histogram analysis module by measuring 20-30 randomly selected cells in five different fields. The analysis of colocalization was conducted utilizing the intensities scatter-charts, and a significant colocalization was defined as the colocalization area, which is a cutoff area above the background intensity (30%) and between the thresholds of each channel (60%, represented by two diagonal lines) divided by calculated intensity area.
Proximity ligation assay (PLA)
PLA was performed according to the manufacturer's protocol using the Duolink Detection Kit (Olink Bioscience Uppsala, Sweden). Briefly, cells were grown on 13-mm glass coverslips to 50% confluency, and incubated with primary antibodies targeting the proteins under investigation (raised in different species) overnight at 4 1C. This was followed by incubation with PLA probes MINUS and PLUS for 1 h at 37 1C, probe ligation for 30 min at 37 1C and amplification over 90 min at 37 1C. Far-red signal amplification was used for the assay and interactions were detected using a confocal microscope ( Â 63, Leica TCS SP5). For protein complex and lipid raft colocalization analysis, cells were initially reacted with 1 mg/ml CTB-FITC (Invitrogen) for 30 min at 37 1C, then fixed and permeabilized, before PLA.
Colony-formation assay
To measure the cell survival after etoposide or doxorubicin exposure, Hs578T cells were transfected with control or anti-IGFBP-3 siRNA, as IGFBP-3 modulation of DNA-PK activation MZ Lin et al described above and 500 cells/well were plated into six-well plates for 24 h. The cells were then treated with either etoposide (5 mM) or doxorubicin (0.1 mM) for 4 h, and incubated in growth medium (RPMI 1640 þ 5% FCS) in a humidified 5% CO 2 atmosphere at 37 1C for 8-10 days to allow colony formation. Colonies were fixed with methanol and stained with 1% crystal violet. Colonies having 450 cells were counted and the results analyzed using Multi-Gauge colony analysis software (Fujifilm).
Lipid raft isolation
For lipid raft isolation, the procedure of Wang was followed. 30 Breast cancer cells (2 Â 10 7 ) were harvested and the pellet lysed with 1 ml 1% Triton X-100-containing lysis buffer (25 mmol/l MES, pH 6.5, 150 mmol/l NaCl, 1% Triton X-100, 1 mmol/l EGTA, and protease and phosphataseinhibitor cocktail) on ice for 30 min with frequent agitation. The lysate was mixed with equal volumes of buffer A (25 mmol/l MES, pH 6.5, 150 mmol/l NaCl, 1 mmol/l EGTA and 80% (w/v) sucrose). This was overlaid with 2.5 ml of buffer B (25 mmol/l MES, pH 6.5, 150 mmol/l NaCl, 1 mmol/l EGTA and 30% (w/v) sucrose) and 1.66 ml of buffer C (25 mmol/l MES, pH 6.5, 150 mmol/l NaCl, 1 mmol/l EGTA and 5% (w/v) sucrose). The detergentresistant lipid rafts were isolated by sucrose density gradient centrifugation for 42 h at 4 1C at 175 000 g in a RPS50-2 rotor (Hitachi, Tokyo, Japan); 0.5 ml fractions were collected from the top to the bottom of the gradient and analyzed by western blotting.
